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embryo implantation
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Background: Endometrial function is essential for embryo implantation. The aim of this study was to analyze gene
expression profiles from individual endometrial samples obtained from women with repeated implantation failure
after IVF in oocyte donation programs.
Methods: Seventeen volunteers were recruited: women who had previously participated as recipients in oocyte
donation cycles and repeatedly exhibited implantation failure (Group A, study group, n = 5) or had at least one
successful cycle (Group B, control group, n = 6) and spontaneously fertile women (Group C, normal fertility group,
n = 6). An endometrial cycle was induced with exogenous estradiol (E2) and progesterone (P) and an
endometrial sample was collected on the seventh day of P treatment.
Results: Transcriptome analysis showed 82 genes with consistent differential gene expression when comparing
A vs. B and A vs. C. One hundred transcripts differentially expressed in group A vs. B have been shown to be
regulated by P, suggesting compromised P signaling in the endometrium. The P receptor (PR) mutation
PROGINS was not detected in women from group A. Semi-quantitation of immunoreactive PRA/B, PRB and Sp1
(a transcription factor related to P signaling) in paraffin-embedded endometrial sections, did not show statistically
significant differences amongst groups. However immunostaining glycodelin was significantly decreased in endometrial
samples from group A
Conclusions: We conclude that some cases of repeated implantation failure could be associated with an aberrant gene
expression profile. Compromised P signaling might be the underlying mechanism for such endometrial gene expression
deregulation in women with repeated implantation failure.
Keywords: Endometrium, Gene expression, PROGINS, Implantation failureBackground
Cellular and molecular events in the uterine milieu that
lead to successful blastocyst implantation are required in
the endometrium to become receptive and ready for im-
plantation. Acquisition of receptivity is driven by estra-
diol (E2) and progesterone (P), which acting through
their receptors, change the transcription rate of target
genes [1]. Particularly, the postovulatory rise in P triggers
a sequence of highly coordinated responses beginning* Correspondence: atapiap@gmail.com
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article, unless otherwise stated.with the detention of the estrogen-induced epithelial cell
proliferation and followed by the transformation to a
secretory phenotype of the gland, recruitment of leuko-
cytes and angiogenesis [2]. The P action is mediated pri-
marily through binding to and activation of its cognate
receptors; the full length B- and N-terminally truncated A
isoforms of the P receptor (PR), classically defined as
ligand-activated transcription factors [3]. Upon exposure
to P, the ligand-activated receptor can directly interact
with specific P-response elements (PREs) in the promoter
regions of target genes. It is accepted that P acts on an es-
trogen primed endometrium to initiate a pattern of gene
expression important for achievement of receptivity andentral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/4.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
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endometrial dysfunction [4]. The antiprogestin mifepris-
tone binds to the PR with high affinity blocking the bio-
logical effects of P. In women, the administration of a
single dose of oral mifepristone (200 mg) during the
secretory phase of the cycle rapidly renders the endomet-
rium unreceptive and modifies gene expression in the
uterus within 6 h of administration [5-7].
The development of microarray technology has led to
many large-scale gene expression profiling studies of hu-
man endometrium [8-10]. Although there seems to be
very few consensus genes that have been identified across
similar studies [11], collectively they demonstrate that a
multitude of genes are associated with the endometrial
transcriptome, whose regulation for the acquisition of the
receptive phenotype is ultimately driven by P. The ap-
proach our group has used to identify the endometrial re-
ceptivity transcript profile in a previous report from our
laboratory [12] was to analyze endometrial tissue obtained
from women during a mock hormonal treatment cycle for
oocyte donation as a recipient. The endometrial samples
are collected during the time interval corresponding to
the window of implantation [13] comparing gene expres-
sion profiles from women who were refractory to implant-
ation and those who achieved pregnancy in previous
oocyte donation cycles [12]. Although this previous study
provided interesting insights to endometrial gene expres-
sion associated with implantation failure, the microarrays
analysis was performed with only 3(from a total of 5) sam-
ples from women with repeated embryo implantation fail-
ure that were pooled and using a microarrays platform
that examined only one-third of the human genome; pro-
viding only a partial view of the whole picture.
The aim of the present report was to examine the indi-
vidual gene expression profiles in the endometrium from
women with implantation failure and compare them
with those obtained from fertile women in order to
identify compromised transcripts and pathways in the
infertile group. We used a microarrays platform for
complete coverage of the human genome and bioinfor-
matics tools for data interpretation. Here we report
that several transcripts, whose expression level is aber-
rant in the infertile group, have been described as reg-
ulated by P and are related to immune function.Table 1 Characteristics of women participating in the study a
replacement cycle
Group A (n = 5)
Age (years) 35.4 (26–43)
Body mass index 25.2 (22.6-29.4)
Plasma progesterone* (nmol/L) 75.7 (38–122)
Endometrial thickness* (mm) 10.8 (9–12)
*On the day of endometrial collection.Methods
Subjects
This study was approved by the Ethics Review Commit-
tee for Investigations in Human Beings of Faculty of
Medicine, University of Chile: protocol No. 093–2008,
approved 12-29-2008, initiated 01-05-2009 finished
03-31-2014. Each volunteer participating read and signed
the informed consent approved by the respective Ethics
Review Committee.
Three groups of women were recruited as has been
described elsewhere [12]. Group A (n = 5) consisted of
women that had never been pregnant and had previously
participated in two or more cycles as recipients in an oo-
cyte donation program with no evidence of embryo im-
plantation. Male partners had normal seminal parameters
and transferred embryos had good morphology, at least
equivalent to embryos transferred to the oocyte donor
who became pregnant. Since good quality embryos with
the ability to implant and develop normally derive from
good quality oocytes, it was required that the oocyte
donor had become pregnant from the same oocyte pool.
Women from group A were recruited within 3 years fol-
lowing the last failed cycle. Group B (n = 6) comprised of
women who became pregnant as recipients in previous
oocyte donation cycles and delivered live infants. Group C
(n = 6) included normal fertile women who conceived in
natural cycles and had three or more live births and had
elective tubal ligation at least 1 year prior to their partici-
pation for reasons unrelated to this study. Women from
groups B and C were recruited within 5 years following
the last successful pregnancy. The general exclusion cri-
teria for all volunteers included: metabolic or endocrine
diseases other than those leading to ovarian failure,
chronic use of medication other than HRT, polycystic
ovary syndrome, drug abuse, obesity, endometriosis,
pelvic inflammatory disease and current genital tract
infection. Age and body mass index from recruited
women as well as the plasma P and endometrial thick-
ness measured on the day of the endometrial collection
are shown in Table 1.
Induction of endometrial cycle
All subjects underwent the induction of an artificial
endometrial cycle with exogenous ethinyl E2 for 20 daysnd parameters evaluated during the hormonal
Group B (n = 6) Group C (n = 6) P value
41.9 (34–46) 41.3 (36–47) 0.1117
25.6 (22.5-27.4) 25.4 (23.3-28.1) 0.573
88.1 (36–192) 63.7 (43.3-75) 0.7601
9.1 (8–10) 11.2 (8.5-12.5) 0.6162
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concomitantly with micronized P as described previously
[12]. An endometrial sample was obtained on 20th day
of the endometrial cycle. One part of the specimen was
snap frozen in liquid nitrogen and kept at −80 ° C until
use and the remaining portion was fixed in paraformal-
dehyde for histological dating, according to the criteria
of Noyes et al., [14] and for immunohistochemistry
(IHC) studies. All biopsies were classified as normal
secretory endometrium with no signs of inflammatory
processes.
Gene expression profiling
Total RNA was extracted from frozen endometrial tissue
samples using Trizol (Invitrogen, Gaithersburg, MD, USA)
as directed by the manufacturer and then checked for yield
and quality as described before [12]. The Human Genome
U133 plus 2.0 GeneChip oligonucleotide microarrays
(Affymetrix, Sunnyvale, CA, USA); corresponding to
47,000 transcripts and variants, including 38,500 well-
characterized human genes, was used for gene expression
analysis according to the manufacturer’s instruction.
Microarrays Data Analysis: Replicate hybridizations were
performed for each RNA sample and raw data obtained
from the GeneChip Microarray Suite v 1.4 was subsequently
analyzed using the National Cancer Institute’s Microarrays
Data Base webtool (mAdb) (http://nciarray.nci.nih.gov).
Statistical analyses of microarrays data
Significant genes were defined as ≥2, p-value < 0.001 and
a false discovery rate (FDR) < 0.1 [15]. T-test was per-
formed to determine statistical differences and from the
significant genes identified, Venn diagrams were con-
structed to identify coincident transcripts.
Hierarchical clustering
Was performed based on uncentered correlations with
average linkage clustering using mAdb. The resulting
dendogram allows data structure visualization of endo-
metrial samples according to total gene expression, re-
vealing samples with similar patterns of gene expression
and relationships between the specimens.
Principal component analysis (PCA)
Was performed for simplifying the large amount of data
derived from microarray analysis [16]. We applied the
unbiased PCA algorithm to all samples using all tran-
scripts analyzed with the microarray chip to look for ex-
pression patterns and underlying cluster structures of
endometrial samples.
Functional clustering
To increase the effectiveness of DNA microarray ana-
lysis, data sets of differentially expressed genes from thecomparison between A vs. B and A vs. C were intersected
to define those transcripts consistently up- or down-
regulated and combined with external data sources, such
as gene annotation, in order to associate the expression
patterns of this particular set of genes with the biological
processes that they may represent. In our analysis, we sub-
mitted our gene lists to the web-based tools DAVID
(Database for Annotation, Visualization and Integrated
Discovery) [17] and GATHER (Gene Annotation Tool
to Help Explain Relationships) [18] for functional annota-
tion analysis in order to gain an in-depth understanding of
their biological themes, which otherwise would require
laborious and somewhat subjective manual literature
searches.
DAVID
Up- and down-regulated genes were submitted to DA-
VID database for systematically extracting biological
meaning for them by retrieving pathway maps from the
Kyoto Encyclopedia of Genes and Genomes (KEGG)
[19] and Biocarta pathways database (http://www.bio-
carta.com/genes/index.asp) along with Gene Ontology
(GO) functional annotations from Entrez Gene [20].
The parameters of the “Functional Annotation Cluster-
ing” (a part of the “Functional Annotation Tool”) were
set to the highest level of stringency in order to obtain
the smallest number of maps. The DAVID database asso-
ciates each annotation to a gene group using a contin-
gency table representation and calculates its significance.
GATHER
Regulated genes were submitted as well to GATHER
database (http://gather.genome.duke.edu/) that contains
the GO annotations and KEGG pathways. The GATHER
database associates each group of transcripts with the
same functional annotation and calculates a Bayes factor
[18] which is a measure of the strength of the evidence
supporting an association of an annotation with the
submitted gene list. We have selected a low Bayes fac-
tor (≥3) for presenting the preponderant evidences for
associations.
Immunohistochemistry (IHC)
A portion of each endometrial sample was fixed in para-
formaldehyde, included in paraffin blocks and 5 μm
sections were prepared. PR-A/B, PR-B, glycodelin and
Specificity protein 1 (Sp1) were evaluated by IHC in
the endometrial samples using the antibodies and dilutions
shown in Table 2 and the broad spectrum Histostain-SP
kit (Life Technologies, Carlsbad, CA, USA) as described
previously [21]. Immunoreactive PRA/B, PRB, Sp1 and gly-
codelin in endometrial sections was semi-quantified using
the expression level score (ELS), calculated by means of
Image Pro Plus software (Media Cybernetics Rockville,





Santa Cruz Biotech. (sc-810) 1:50
PR-B Novocastra (NCL-PGR-B) 1:100
Glycodelin H. Koistinen [22] 1:1000
Specificity protein-1 (Sp1) Santa Cruz Biotech. (sc-14027) 1:100
Tapia-Pizarro et al. Reproductive Biology and Endocrinology 2014, 12:92 Page 4 of 15
http://www.rbej.com/content/12/1/92MD, USA) as described previously [21]. Briefly, ELS =
Mean Optical Density of immunostaining x Percent Area
Positively Stained x 100.DNA isolation and PROGINS detection
Genomic DNA was isolated from leukocytes derived
from peripheral blood obtained by venipuncture using
the PAXgene Blood DNA Validation kit (Qiagen, Valencia,
CA, USA) following the manufacturer’s protocol. The
detection of Alu insertion in intron G and restriction
fragment length polymorphism (RFLP) analysis in exon
5 to confirm the presence of PROGINS mutation was
performed as described by Pisarska et al. [23].Figure 1 Principal component analysis (PCA) plot of gene expression
differentially expressed transcripts. A, The profiles from infertile women
of women with embryo implantation (groups B (n = 6) and C (n = 6); green
represented in a tree-like dendogram revealing the similarities on gene exp
into two major clustering branches, one with samples from group A and th
C, Venn diagrams showing the differentially expressed genes in each group
endometrial samples from women with implantation failure (group A) com
naturally (group C).Results
Gene expression profile analysis
Women with implantation failure (group A, n = 5), women
with 2 or more livebirths conceived either by oocyte dona-
tion (group B, n = 6) or naturally (group C, n = 6) were
subjected to an oocyte donation mock cycle as recipients
and on the seventh day of P administration an endometrial
sample was obtained. Total RNA was extracted from each
tissue sample and used to individually probe the HG_U133
plus 2.0 human gene microarray comprising of 54,675
genes and expressed sequence tags.
We performed PCA for all the endometrial samples
analyzed using their respective gene expression profiles
for their representation on a three-dimensional graphic
(Figure 1A). Each point in a PCA graph represents the
gene expression profile of an endometrial sample and
the distance between two plotted points is proportional
to the degree of similarity between the gene expression
profiles. The PCA plot comprising of a projection on the
first three principal components, which together explain
48.8% (21%, 14%, and 13%) of the total variance, showed
that endometrial samples from infertile subjects clustered
apart from samples belonging to the control groups. In
addition, gene expression profiles from endometrial sam-
ples obtained from microarray analysis were subjected toprofiles from endometrial samples and Venn diagrams from
(group A (n = 5); red dots) cluster separately to clusters representative
and blue dots, respectively). B, hierarchical clustering analysis
ression profiles of endometrial samples. A clear segregation of samples
e other with samples form groups B and C that self-cluster together.
, which are either 2-fold down- (panel C) or up-regulated (panel D) in
pared to those from women that conceived either by IVF (Group B) or
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generate a dendogram, which is a tree-structured graph
that illustrates the similarities in gene expression pro-
files between endometrial samples from all groups. The
dendogram obtained displayed a striking segregation of
samples into two major clustering branches, correspond-
ing to the implantation failure group (Group A) and
the successful implantation groups (Groups B and C,
Figure 1B).
The microarrays data analysis revealed that 747 tran-
scripts were down-regulated in group A compared to groupTable 3 Genes whose transcript level was down-regulated in
Group C (n = 6) in the microarray analyses
UniGene ID Gene symbol Gene title
Hs.699841 IGHA1 Immunoglobulin heavy constant alpha 1
Hs.436657 CLU Clusterin
Hs.356624 NID1 Nidogen 1
Hs.82071 CITED2 Cbp/p300-interacting transactivator. with Gl
carboxy-terminal domain. 2
Hs.532325 PAEP Progestagen-associated endometrial protein
Hs.38972 TSPAN1 Tetraspanin 1
Hs.445705 RRM1 Ribonucleotide reductase M1
Hs.1012 C4BPA Complement component 4 binding protein
Hs.513261 HN1L Hematological and neurological expressed 1
Hs.80658 UCP2 Uncoupling protein 2 (mitochondrial. proton
Hs.502989 UNC93B1 Unc-93 homolog B1 (C. elegans)
Hs.414099 CNPY3 Canopy 3 homolog (zebrafish)
Hs.110571 GADD45B Growth arrest and DNA-damage-inducible. b
Hs.320151 AGPAT2 1-acylglycerol-3-phosphate O-acyltransferase
(lysophosphatidic acid acyltransferase. beta)
Hs.77422 PLP2 Proteolipid protein 2 (colonic epithelium-en
Hs.1497 RARG Retinoic acid receptor. gamma
Hs.389700 MGST1 Glutathione S-transferase. microsomal
Hs.292078 LARP1 La ribonucleoprotein domain family. memb
Hs.334587 RBPMS RNA binding protein with multiple splicing
Hs.5298 ADIPOR1 Adiponectin receptor 1
Hs.439894 CASZ1 Castor zinc finger 1
Hs.371727 SCNN1G Sodium channel. nonvoltage-gated 1. gamm
Hs.474596 LIMK2 LIM domain kinase 2
Hs.459940 LITAF Lipopolysaccharide-induced TNF factor
Hs.442449 CHST14 Carbohydrate (N-acetylgalactosamine 4–0) s
Hs.518525 GLUL Glutamate-ammonia ligase
Hs.119177 ARF3 ADP-ribosylation factor 3
Hs.497417 KIAA0317 KIAA0317
Hs.501728 RHOG Ras homolog gene family. member G (rho G
Hs.414614 SCNN1B Sodium channel. nonvoltage-gated 1. beta
Hs.436896 POLR3A Polymerase (RNA) III (DNA directed) polypep
Data includes genes with decreased transcript levels displaying a ≥2-fold differenceB; whereas 218 transcripts were up-regulated (Figure 1C
and 1D). When group A was compared to group C, 156
and 884 transcripts were decreased and increased respect-
ively in group A (Figure 1C and 1D). Only 31 and 51 tran-
scripts down- and up-regulated respectively were common
when comparing group A with the control groups B and C
(Figure 1C and 1D). The lists of common differentially
expressed genes in the comparison of gene expression pro-
files from group A vs. Group B and Group A vs. group C is
in Table 3 for down- and Table 4 for up-regulated tran-
scripts. An independent validation by Real Time RT-PCRGroup A (n = 5) when compared with Group B (n = 6) and
A vs. B p value A vs. C p value Average
0.1 0.00086 0.08 0.00043 0.09
0.11 0.00043 0.17 0.00013 0.14
0.19 0.00013 0.14 0.00022 0.16
u/Asp-rich 0.15 0.00086 0.19 0.00043 0.17
(PAEP) 0.09 0.00086 0.29 0.00086 0.19
0.14 0.00022 0.24 0.00086 0.19
0.18 0.00043 0.23 0.00022 0.2
. alpha 0.21 0.00043 0.22 0.00043 0.22
-like 0.18 0.00022 0.35 0.00043 0.26
carrier) 0.1 0.00043 0.49 0.00013 0.29
0.23 0.00013 0.37 0.00043 0.3
0.29 0.00013 0.32 0.00022 0.31
eta 0.2 0.00022 0.44 0.00086 0.32
2 0.23 0.00086 0.43 0.00013 0.33
riched) 0.26 0.00043 0.42 0.00043 0.34
0.33 0.00043 0.35 0.00043 0.34
0.4 0.00022 0.29 0.00043 0.34
er 1 0.34 0.00043 0.36 0.00086 0.35
0.29 0.00086 0.43 0.00022 0.36
0.3 0.00022 0.42 0.00013 0.36
0.24 0.00022 0.49 0.00086 0.37
a 0.29 0.00013 0.45 0.00043 0.37
0.26 0.00043 0.5 0.00013 0.38
0.37 0.00022 0.39 0.00086 0.38
ulfotransferase 14 0.42 0.00086 0.35 0.00086 0.38
0.42 0.00043 0.48 0.00086 0.45
0.47 0.00013 0.45 0.00043 0.46
0.49 0.00086 0.44 0.00013 0.46
) 0.46 0.00043 0.47 0.00043 0.47
0.48 0.00013 0.47 0.00022 0.47
tide A. 155 kDa 0.48 0.00043 0.47 0.00043 0.48
in average A vs. B and A vs. C.
Table 4 Genes whose transcript level was up-regulated in Group A (n = 5) when compared with Group B (n = 6) and
Group C (n = 6) in the microarray analyses
UniGene ID Gene symbol Gene title A vs. B p value A vs. C p value Average
Hs.35086 USP1 Ubiquitin specific protease 1 (USP1), mRNA. 42.52 0.00022 44.32 0.00043 43.42
Hs.436977 SYTL3 Synaptotagmin-like 3 20.68 0.00043 26.72 0.00013 23.70
Hs.133421 LIFR Leukemia inhibitory factor receptor 43.71 0.00086 3.32 0.00022 23.52
Hs.160211 THRAP3 Thyroid hormone receptor associated protein 3 (THRAP3), mRNA. 29.04 0.00013 3.66 0.00043 16.35
Hs.532399 ZC3H11A KIAA0663 gene product (KIAA0663), mRNA. 4.38 0.00043 28.05 0.00086 16.21
Hs.652169 PLGLB2 Plasminogen-like B2 21.71 0.00086 9.45 0.00086 15.58
Hs.524809 CLIP1 Restin (Reed-Steinberg cell-expressed intermediate
filament-associated protein) (RSN), transcript variant 2,
mRNA.
2.19 0.00043 25.81 0.00043 14.00
Hs.16355 MYH10 Myosin, heavy polypeptide 10, non-muscle (MYH10), mRNA. 2.6 0.00013 24.08 0.00022 13.34
Hs.502829 SF1 Splicing factor 1 (SF1), transcript variant 4, mRNA. 21.86 0.00043 4.08 0.00086 12.97
Hs.517949 MAP4 Microtubule-associated protein 4 (MAP4), transcript variant 1, mRNA. 10.41 0.00043 11.96 0.00013 11.18




11 0.00043 9.38 0.00043 10.19
Hs.130293 LUC7L3 Cisplatin resistance-associated overexpressed protein (CROP),
transcript variant 2, mRNA.
6.32 0.00043 11.88 0.00022 9.10
Hs.143728 WASL Wiskott-Aldrich syndrome-like (WASL), mRNA. 2.07 0.00022 14.32 0.00086 8.20
Hs.532082 IL6ST Interleukin 6 signal transducer (gp130, oncostatin M receptor)
(IL6ST), transcript variant 2, mRNA.
2.95 0.00013 13 0.00043 7.97
Hs.2913 EPHB3 EphB3 = HEK2 = tyrosine kinase receptor = large erk kinase 11.39 0.00086 4.41 0.00086 7.90
Hs.431081 USP53 Ubiquitin specific protease 53 2.23 0.00013 13.55 0.00043 7.89
Hs.194726 BAG4 BCL2-associated athanogene 4 (BAG4), mRNA. 11.71 0.00013 3.16 0.00086 7.44
Hs.464971 PIK3C3 Phosphoinositide-3-kinase, class 3 3.92 0.00043 10.41 0.00086 7.16
Hs.9997 SECISBP2L KIAA0256 gene product (KIAA0256), mRNA. 5.43 0.00086 7.36 0.00013 6.39
Hs.497788 EPRS Glutamyl-prolyl-tRNA synthetase (EPRS), mRNA. 4.41 0.00043 8.11 0.00043 6.26
Hs.101014 CEP57 Translokin (KIAA0092), mRNA. 5.03 0.00086 7.31 0.00086 6.17
Hs.143600 GOLIM4 Golgi phosphoprotein 4 (GOLPH4), mRNA. 2.46 0.00043 9.85 0.00022 6.16
Hs.24485 SMC3 Chondroitin sulfate proteoglycan 6 (bamacan) (CSPG6), mRNA. 2.53 0.00022 9.65 0.00043 6.09
Hs.193832 GPATCH4 G patch domain containing 4 (GPATC4), transcript variant 3, mRNA. 3.32 0.00013 7.94 0.00086 5.63
Hs.406695 PRDM7 PR domain containing 7 (PRDM7), mRNA. 2.04 0.00086 8.46 0.00086 5.25
Hs.42194 SPCS3 Signal peptidase complex subunit 3 homolog (S. cerevisiae) (SPCS3),
mRNA.
2.1 0.00043 8.34 0.00022 5.22
Hs.458418 KIAA1731 PREDICTED: KIAA1731 protein (KIAA1731), mRNA. 2.04 0.00013 8.4 0.00086 5.22
Hs.49853 CCAR1 Cell division cycle and apoptosis regulator 1 2.75 0.00086 7.67 0.00013 5.21
Hs.496414 ATP7A ATPase, Cu++ transporting, alpha polypeptide (Menkes syndrome) 2.89 0.00086 7.16 0.00043 5.02
Hs.481181 NEK1 NIMA (never in mitosis gene a)-related kinase 1 (NEK1), mRNA. 3.07 0.00086 5.35 0.00043 4.21
Hs.440833 PKN2 protein kinase N2 (PKN2), mRNA. 6.02 0.00022 2.14 0.00043 4.08
Hs.524009 AASDHPPT Aminoadipate-semialdehyde dehydrogenase-phosphopantetheinyl
transferase
3.89 0.00013 4.2 0.00086 4.04
Hs.26904 SEC63 SEC63 homolog (S. cerevisiae) 2.95 0.00086 3.78 0.00043 3.37
Hs.93485 SCN2A MRNA; cDNA DKFZp761D191 (from clone DKFZp761D191) 2.08 0.00043 4.5 0.00013 3.29
Hs.31082 TMEM33 Transmembrane protein 33 2.19 0.00086 4.35 0.00043 3.27
Hs.371372 CWC27 Serologically defined colon cancer antigen 10 (SDCCAG10), mRNA. 2.95 0.00043 3.51 0.00086 3.23
Hs.523299 EIF3A Eukaryotic translation initiation factor 3, subunit 10 theta,
150/170 kDa (EIF3S10), mRNA.
2.68 0.00022 3.58 0.00022 3.13
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Table 4 Genes whose transcript level was up-regulated in Group A (n = 5) when compared with Group B (n = 6) and
Group C (n = 6) in the microarray analyses (Continued)
Hs.440320 CUL5 Cullin 5 (CUL5), mRNA. 2.6 0.00043 3.25 0.00043 2.93
Hs.203965 PHTF2 Putative homeodomain transcription factor 2 3.56 0.00013 2.3 0.00086 2.93
Hs.335068 TGS1 Nuclear receptor coactivator 6 interacting protein (NCOA6IP), mRNA. 3.63 0.00086 2.16 0.00013 2.89
Hs.189075 TWF1 Twinfilin, actin-binding protein, homolog 1 (Drosophila) 2.36 0.00086 2.97 0.00043 2.67
Hs.127310 UHMK1 U2AF homology motif (UHM) kinase 1 (UHMK1), mRNA. 2.85 0.00086 2.46 0.00043 2.66
Hs.430849 OSBPL8 Oxysterol binding protein-like 8 (OSBPL8), transcript variant 1, mRNA. 2.03 0.00022 3.05 0.00022 2.54
Hs.150557 KLF9 Basic transcription element binding protein 1 (BTEB1), mRNA. 2.6 0.00086 2.39 0.00043 2.50
Hs.210850 HECTD1 HECT domain containing 1 (HECTD1), mRNA. 2.35 0.00013 2.6 0.00086 2.47
Hs.142442 HP1BP3 Heterochromatin protein 1, binding protein 3 2.08 0.00086 2.41 0.00013 2.25
Hs.369284 ESF1 Chromosome 20 open reading frame 6 (C20orf6), mRNA. 2.13 0.00013 2.3 0.00086 2.21
Hs.119023 SMC2 SMC2 structural maintenance of chromosomes 2-like 1 (yeast)
(SMC2L1), mRNA.
2.25 0.00022 2 0.00022 2.13
Hs.481927 NIPBL Nipped-B homolog (Drosophila) 2.11 0.00043 2.04 0.00086 2.08
Hs.374201 KIF21A kinesin family member 21A (KIF21A), mRNA. 2.13 0.00013 2 0.00013 2.06
Data includes genes with increased transcript levels displaying a ≥2-fold difference in average A vs. B and A vs. C.
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samples used in this study has been reported elsewhere
[12], supporting our microarrays findings.
Functional associations of transcripts dysregulated in
group A vs. control groups
In order to gain further understanding of the potential
functional roles of dysregulated endometrial transcripts
from group A, we obtained the functional annotations
from each gene and determined the enriched processes
associated to them from two different web-based tools.
Within the down-regulated transcripts, the functional
classifications immune response and complement activation,
classical pathway were found to be statistically over-
represented using the web based applications DAVID
and GATHER respectively (p < 0.01). The Bayes factor
obtained with the analysis using the GATHER database
was 3, which indicates that the association of this par-
ticular function with the total of the transcripts in our
gene list is weak. The up-regulated transcript list was
not enriched with transcripts related to a particular
function.
P-regulated genes in women with implantation failure
(group A) vs. control (group B)
We reasoned that the endometrium of women from
group A might have a dysregulation in P-regulated tran-
scripts as it has been described for endometriosis and
also these genes might be coincident with those whose
expression in the endometrium is altered upon treat-
ment with the PR antagonist mifepristone. Since women
from groups A and B only differ on the embryo implant-
ation outcome, the list of dysregulated transcripts in
group A vs. group B during the receptive phase of theendometrium was selected. Within this repertoire, we
searched for those genes known to be regulated in normal
cycling endometrium by P as it has been described before
[4]. For that we accounted for those transcripts that, di-
rected by P, get regulated for the acquisition of endomet-
rial receptivity [24-32] and/or dysregulated in conditions
that render the endometrium with an unreceptive pheno-
type (i.e., endometriosis and mifepristone treatment) and
that intersected with our list of up and down regulated
genes (i.e., A vs. B). We considered only those that had the
opposite regulation compared with receptive endomet-
rium, and same regulation in endometrium from women
with compromised P signaling in the endometrium such
as treated with mifepristone [7] and/or from women with
endometriosis [4]. We found 14 and 86 up- and down-
regulated genes respectively in the endometrium during
the receptive period of women with implantation failure
vs. control group B (Tables 5 and 6).
PROGINS detection
Since the comparative gene expression analysis of
P-regulated genes in endometrial samples from group A,
suggested an altered P response, we determined the
presence of the Alu insertion in intron G of the PR
gene (PROGINS) in women from groups A, B and C.
Restriction fragment length polymorphism (RFLP) analysis
was also carried out on exon 5 of PR gene for confirmation.
We found 4 heterozygous subjects for pgr (Figures 2A and
B). Two were from group B and two from group C, whereas
no PROGINS alleles were detected in women from group A.
IHC analysis
Since the levels of both isoforms of PR in human endo-
metrium have been found to be abnormal in patients
Table 5 Genes previously described to be progesterone regulated that are down-regulated in endometrium of subjects with
repeated embryo implantation failure









Hs.386793 GPX3 Glutathione peroxidase 3 (plasma) (GPX3), mRNA. [25,27,29,32] 0.01 0.00013
Hs.458355 C1S Complement component 1, s subcomponent,
transcript variant 1, mRNA.
[28,29] 0.02 0.00043
Hs.647023 CLDN3 Claudin 3 [24] 0.07 0.00086
Hs.89603 MUC1 Mucin 1, transmembrane, mRNA. [25] [4] 0.11 0.00022
Hs.436657 CLU Clusterin (complement lysis inhibitor, SP-40,40, sulfated
glycoprotein 2, testosterone-repressed prostate message 2,
apolipoprotein J), transcript variant 1, mRNA.
[27,29,31,32] 0.12 0.00086
Hs.276770 CD52 CD52 molecule [7] 0.14 0.00043
Hs.498173 SMPD1 Sphingomyelin phosphodiesterase 1, acid lysosomal
(acid sphingomyelinase), transcript variant 1, mRNA.
[24,26] 0.14 0.00013
Hs.523414 LOC492304 Putative insulin-like growth factor II associated protein,
mRNA.
[27] 0.15 0.00022
Hs.532325 PAEP Progestagen-associated endometrial protein [24,25,27,31,32] [39] 0.15 0.00086
Hs.590970 AXL AXL receptor tyrosine kinase [24] 0.15 0.00022
Hs.163893 PICALM Phosphatidylinositol binding clathrin assembly protein [4] 0.16 0.00086
Hs.525607 TNFAIP2 Tumor necrosis factor, alpha-induced protein 2, mRNA. [27-29,32] 0.18 0.00043
Hs.654439 APOE Apolipoprotein E [24,29] 0.18 0.00086
Hs.201978 PTGS1 Prostaglandin-endoperoxide synthase 1 (prostaglandin G/H
synthase and cyclooxygenase), transcript variant 2, mRNA.
[29] [7] 0.19 0.00013
Hs.82071 CITED2 Cbp/p300-interacting transactivator, with Glu/Asp-rich
carboxy-terminal domain, 2, mRNA.
[25] 0.19 0.00086
Hs.524518 STAT6 Signal transducer and activator of transcription 6, interleukin-4
induced, mRNA.
[29] 0.19 0.00022
Hs.478588 BCL6 B-cell CLL/lymphoma 6 (zinc finger protein 51), transcript
variant 1, mRNA.
[25,27,29] 0.20 0.00086
Hs.1012 C4BPA Complement component 4 binding protein, alpha [24,25,27,29,31,32] [39] 0.22 0.00043
Hs.21765 FADS3 Fatty acid desaturase 3, mRNA. [26] 0.23 0.00043
Hs.4055 KLF6 Kruppel-like factor 6 [25] 0.23 0.00013
Hs.332708 FBLN5 Fibulin 5, mRNA. [27,29] 0.23 0.00022
Hs.25292 JUNB Jun B proto-oncogene, mRNA. [25,26] 0.25 0.00043
Hs.431048 ABL1 V-abl Abelson murine leukemia viral oncogene homolog 1,
transcript variant b, mRNA.
[24] 0.27 0.00086
Hs.190783 HAL Histidine ammonia-lyase [26,32] 0.27 0.00086
Hs.513984 FLII Flightless I homolog (Drosophila), mRNA. [24,32] 0.27 0.00043
Hs.643357 ADAMTS1 ADAM metallopeptidase with thrombospondin type 1 motif, 1 [29] 0.29 0.00022
Hs.44227 HPSE Heparanase [29] 0.29 0.00086
Hs.515536 RRAS Related RAS viral (r-ras) oncogene homolog, mRNA. [27] 0.29 0.00013
Hs.409578 STK38 Serine/threonine kinase 38 [26] 0.29 0.00043
Hs.549171 C1orf56 Chromosome 1 open reading frame 56 [7] 0.29 0.00022
Hs.494457 NINJ1 Ninjurin 1, mRNA. [26] 0.29 0.00013
Hs.270291 ACTN4 Actinin, alpha 4 (ACTN4), mRNA. [29] 0.29 0.00086
Hs.381099 LCP1 Lymphocyte cytosolic protein 1 (L-plastin), mRNA. [28,29] 0.31 0.00043
Hs.185172 GNB2 Guanine nucleotide binding protein (G protein), beta
polypeptide 2, mRNA.
[26] 0.31 0.00013
Hs.1497 RARG Retinoic acid receptor, gamma [7] 0.33 0.00043
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Table 5 Genes previously described to be progesterone regulated that are down-regulated in endometrium of subjects with
repeated embryo implantation failure (Continued)
Hs.474751 MYH9 Myosin, heavy polypeptide 9, non-muscle, mRNA. [29] 0.33 0.00043
Hs.255093 PFKL Phosphofructokinase, liver, transcript variant 2, mRNA. [24] 0.33 0.00086
Hs.503911 NNMT Nicotinamide N-methyltransferase [25,27] 0.33 0.00043
Hs.504877 ARHGDIB Rho GDP dissociation inhibitor (GDI) beta , mRNA. [24,26,27,29] 0.33 0.00022
Hs.210995 CA12 Carbonic anhydrase XII, transcript variant 2, mRNA. [27,32] 0.35 0.00043
Hs.520640 ACTB Actin, beta, mRNA. [7] 0.35 0.00086
Hs.514819 AP2B1 Adaptor-related protein complex 2, beta 1 subunit, mRNA. [24] 0.35 0.00013
Hs.511605 ANXA2 Annexin A2, transcript variant 2, mRNA. [29] 0.35 0.00086
Hs.87752 MSN Moesin, mRNA. [29] 0.35 0.00022
Hs.654958 ABCF2 ATP-binding cassette, sub-family F (GCN20), member 2 [7] 0.35 0.00013
Hs.443577 TNFRSF21 Tumor necrosis factor receptor superfamily, member 21 [29] [4] 0.35 0.00086
Hs.591868 ZBTB10 Zinc finger and BTB domain containing 10 [4] 0.35 0.00043
Hs.25348 VAMP2 Vesicle-associated membrane protein 2 (synaptobrevin 2) [4] 0.38 0.00086
Hs.159161 ARHGDIA Rho GDP dissociation inhibitor (GDI) alpha, mRNA. [24] [7] 0.38 0.00022
Hs.131269 RARRES1 Retinoic acid receptor responder (tazarotene induced) 1 [27] 0.38 0.00086
Hs.513915 CLDN7 Claudin 7, mRNA. [25] 0.38 0.00013
Hs.10326 COPE Coatomer protein complex, subunit epsilon, transcript
variant 2, mRNA.
[24] 0.38 0.00013
Hs.416024 NRSN2 Neurensin 2 [7] 0.38 0.00043
Hs.434248 PLEC Plectin [26,29] [39] 0.38 0.00086
Hs.584854 AVIL Advillin [26,29] 0.41 0.00022
Hs.183109 MAOA Monoamine oxidase A [24,25,27,28,31,32] 0.41 0.00013
Hs.365405 SELO Selenoprotein O [4] 0.41 0.00013
Hs.645228 KIR3DL1 Killer cell immunoglobulin-like receptor, three domains,
long cytoplasmic tail, 1
[29] 0.41 0.00086
Hs.528299 HTATIP HIV-1 Tat interacting protein, 60 kDa, transcript variant 3,
mRNA.
[26] 0.41 0.00043
Hs.164226 THBS1 Thrombospondin 1, mRNA. [29] 0.41 0.00086
Hs.647078 CDK5 Cyclin-dependent kinase 5 [7] 0.41 0.00043
Hs.278573 CD59 CD59 antigen p18-20 (antigen identified by monoclonal
antibodies 16.3A5, EJ16, EJ30, EL32 and G344), transcript
variant 2, mRNA.
[29] 0.41 0.00022
Hs.515162 CALR Calreticulin [7] 0.41 0.00043
Hs.465744 INSR Insulin receptor [26] 0.41 0.00013
Hs.274256 ELOVL7 ELOVL family member 7, elongation of long chain fatty
acids (yeast)
[4] 0.44 0.00086
Hs.450230 IGFBP3 Insulin-like growth factor binding protein 3 [27,29,32] 0.44 0.00086
Hs.504687 MYL9 Myosin, light polypeptide 9, regulatory [27] 0.44 0.00022
Hs.446641 ARAF V-raf murine sarcoma 3611 viral oncogene homolog, mRNA. [25] 0.44 0.00086
Hs.2030 THBD Thrombomodulin [25,27,29] 0.44 0.00013
Hs.104672 FILIP1L Filamin A interacting protein 1-like [27] 0.44 0.00086
Hs.75862 SMAD4 SMAD family member 4 [4] 0.44 0.00022
Hs.520757 TBXAS1 Thromboxane A synthase 1 (platelet, cytochrome P450,
family 5, subfamily A), transcript variant TXS-II, mRNA.
[29] 0.47 0.00013
Hs.283741 EXOSC5 Exosome component 5 [7] 0.47 0.00086
Hs.174312 TLR4 Toll-like receptor 4, transcript variant 2, mRNA. [29] 0.47 0.00043
Hs.24601 FBLN1 Fibulin 1 [31] [7] 0.47 0.00086
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Table 5 Genes previously described to be progesterone regulated that are down-regulated in endometrium of subjects with
repeated embryo implantation failure (Continued)
Hs.501728 RHOG Ras homolog gene family, member G (rho G) [7] 0.47 0.00043
Hs.220864 CHD2 Chromodomain helicase DNA binding protein 2 [4] 0.47 0.00086
Hs.524809 CLIP1 CAP-GLY domain containing linker protein 1 [29] 0.47 0.00043
Hs.92236 MLL4 Myeloid/lymphoid or mixed-lineage leukemia 4 [7] 0.47 0.00086
Hs.654688 MKL1 Megakaryoblastic leukemia (translocation) 1 [26] 0.47 0.00043
Hs.279837 GSTM2 Glutathione S-transferase mu 2 (muscle) [26] 0.47 0.00086
Hs.645227 TGFB1 Transforming growth factor, beta 1 [7] 0.50 0.00086
Hs.149261 RUNX1 Runt-related transcription factor 1 [27] 0.50 0.00013
Hs.522818 L1CAM L1 cell adhesion molecule (hydrocephalus, stenosis of
aqueduct of Sylvius 1, MASA (mental retardation, aphasia,
shuffling gait and adducted thumbs) syndrome, spastic
paraplegia 1)
[26] 0.50 0.00043
Hs.840 IDO1 Indoleamine 2,3-dioxygenase 1 [24,25,29] 0.50 0.00086
Hs.2256 MMP7 Matrix metalloproteinase 7 (matrilysin, uterine) [27] 0.50 0.00043
Data is expressed as fold change for endometrial genes down-regulated ≥2-fold in group A vs. group B that have been shown either up-regulated during the window of
implantation or down-regulated in women with endometriosis or treated with mifepristone. Bolded transcripts are decreased also in group A vs. Group C.
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active presence of PR-A/B (Figures 3A and 3C), PR-B
(Figures 3D and 3F) along with Sp1 (Figure 3G and 3I)
and the P-regulated glycoprotein glycodelin (Figures 3 J
and 3L) in paraformaldehyde-fixed paraffin embeddedTable 6 Genes previously described to be progesterone regul
with repeated embryo implantation failure
UniGene ID Gene symbol Gene title
Hs.208854 CD69 CD69 antigen (p60, early T-cell activation ant
Hs.406515 NQO1 NAD(P)H dehydrogenase, quinone 1
Hs.335614 SEC14L2 SEC14-like 2 (S. cerevisiae), mRNA.
Hs.481181 NEK1 NIMA (never in mitosis gene a)-related kin
1 (NEK1), mRNA.
Hs.86368 CLGN Calmegin, mRNA.
Hs.189075 TWF1 Twinfilin, actin-binding protein, homolog
1 (Drosophila)
Hs.127680 LOC389332 PREDICTED: hypothetical LOC389332 (LOC389
Hs.369430 PAM Peptidylglycine alpha-amidating monooxygen




Hs.509447 GRLF1 Glucocorticoid receptor DNA binding factor 1
Hs.481927 NIPBL Nipped-B homolog (Drosophila)
Hs.444558 KHDRBS3 KH domain containing, RNA binding, signal t
associated 3, mRNA.
Hs.495710 GPM6B Glycoprotein M6B (GPM6B), transcript variant
Hs.496414 ATP7A ATPase, Cu++ transporting, alpha polypep
(Menkes syndrome)
Data is expressed as fold change for endometrial genes up-regulated ≥2-fold in grou
of implantation or up-regulated in women with endometriosis or treated with mifeprisendometrial tissue from groups A, B and C by IHC. Im-
munostaining was semi-quantified by calculating the re-
spective ELS scores for each detected molecule in all
groups of women (Figure 4). ELS for glycodelin in










igen) [7] 2,3 0.00022
[29] 2,2 0.00043
[4] 1,9 0.00013
ase [29] 1,6 0.00043
[7] 1,5 0.00086
[4] 1,5 0.00043
332), mRNA. [4] 1,4 0.00013






ransduction [24,29,32] [4] 1,1 0.00043
4, mRNA. [29] 1,0 0.00022
tide [29] 1,0 0.00043
p A vs. group B that have been shown either down-regulated during the window
tone. Bolded transcripts are increased also in group A vs. Group C.
Figure 2 Screening for PROGINS allele. A, identification of Alu insertion in Intron G. The Alu insertion in the progesterone receptor gene
generates a 494-bp PCR product compared to the 174-bp fragment obtained for the wild type. Samples 04, 05, 24 and 25 with bands at 494 bp
and 174 bp indicate the presence of PROGINS in the heterozygous state. All the other lanes with a single fragment of 174 bp indicate the
presence of the wild-type progesterone receptor in the homozygous state. B, restriction digestion of exon 5 with NlaIII. Lanes for samples 04,
05, 24 and 25 confirm the presence of PROGINS in heterozygous state; NlaIII cleaves the PCR product into two fragments, 106 and 53 bp. All the other
samples displayed the uncleaved 159-bp fragment only, indicating the presence of the wild type receptor.
Figure 3 Immunodetection of progesterone receptor (A and B isoforms, PR), progesterone receptor B (PRB), Specificity Protein 1 (Sp1)
and glycodelin in endometrial sections. Representative photomicrographs of endometrial sections immunostained in triplicate for PR (panels
A, B and C), PRB (panels D, E and F), Sp1 (panels G, H and I) and glycodelin (panels J, K and L) are shown in women from group A (panels A, D,
G and J; n = 5), group B (panels B, E, H and K; n = 6) and group C (panels C, F, I and L; n = 6).
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Figure 4 Immunohistochemistry semiquantitation. Expression Level Score (ELS) for immunostaining of glycodelin (panel A), PRA/B (panel B),
PRB (panel C) and Sp1 (panel D) in endometrial sections from groups A (n = 5), B (n = 6) and C (n = 6). Data is expressed as average ELS ± SD for
each group. *p < 0.05, Kruskal Wallis U-test.
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PR-A/B and PR-B in endometrial tissue was evaluated
(Figures 3A-C and 3D-F, respectively), since a possible
post-translational dysregulation of PR expression (not
detected by transcript analysis) might explain the differ-
ential gene expression of P-regulated genes in the endo-
metrium from women of group A such as glycodelin.
The ELS scores obtained for PR-A/B and PRB did not
show significant differences amongst groups (Figures 4B
and 4C respectively). In addition, semi-quantitation of
immunoreactive Sp1, a known co-activator and trans-
activator of the PR that mediates P-induced glycodelin
expression, did not show significant differences amongst
groups A, B and C (Figure 4D).
Discussion
Uterine receptivity is defined as a restricted time-related
period when the uterus is receptive to blastocyst attach-
ment and implantation. The establishment of this endo-
metrial transition, which supports embryo implantation, is
primarily coordinated by ovarian hormones, E2 and P that
modulate uterine events in a spatiotemporal manner.
Endometrial factors, at the molecular level, have been
suggested to explain some cases of infertility, recurrent
miscarriages and implantation failure after IVF. In the
present study we assessed the endometrial gene expres-
sion profile during the receptive period in mock oocytedonation cycles of women with repeated embryo im-
plantation failure (Group A). Their profiles were com-
pared with those obtained from women who achieved
embryo implantation and pregnancy in oocyte donation
cycles (Group B), or which got pregnant in natural spon-
taneous cycles (Group C). The data suggest a strong asso-
ciation between an aberrant endometrial gene expression
and implantation failure. The stimulation protocol with
steroid hormones performed before the endometrial sam-
ple collection was the same for all participating women in
this study. Hence, the differential transcript profile in
Group A suggests a long-term dysregulation of endomet-
rial gene regulation rendering it not suitable for embryo
implantation. The functional annotation analysis of dys-
regulated transcripts showed an enrichment of decreased
genes involved in immune response and complement acti-
vation in women with repeated implantation failure.
Integration and cross-validation of endometrial tran-
scripts regulated by P could increase the confidence in
expression results for many more genes than is tractable
with classical one-by-one validation of differentially
expressed genes and should provide the up- and down-
regulated genes that together orchestrate the acquisi-
tion of the receptive phenotype of the endometrium
for embryo implantation. Such exploration and inte-
gration could help to get a comprehensive view of
existing data needed to better prioritize experimental
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http://www.rbej.com/content/12/1/92efforts. We identified a subset of P-regulated tran-
scripts with differential expression in the endometrium
of women from group A compared to the control group B
revealing compromised P-signalling in the endometrium.
Pisarska et al. [23] reported that 42% of women with
unexplained infertility carry the allele for the PROGINS
mutation compared with 14% of control fertile women
(with at least 1 term pregnancy). We analyzed the pres-
ence of the PROGINS allele in women from groups A, B
and C and found no correlation between the PROGINS
carrier women and altered transcript levels of P-regulated
genes in the endometrium. This result is in line with a
study from Coulam et al. [35] that did not find an associ-
ation between PR polymorphisms with recurrent implant-
ation failure in women after in vitro fertilization and
embryo transfer.
Glycodelin, encoded by the gene PAEP [36,37] is the
main P-regulated glycoprotein secreted by the endomet-
rial epithelium during the secretory phase and early
pregnancy [38]. The transcript levels for PAEP have also
been consistently identified to be one of the most abun-
dant in the endometrium by several gene expression
profiling studies [24,25,27,31], and it has been shown to
be decreased in women with endometriosis [39]. In the
present study we found that the transcript levels for
PAEP were decreased in the endometrium of women from
group A compared to both control groups (Table 5). In
addition, immunoreactive glycodelin evaluation in endo-
metrial sections showed the protein to be significantly de-
creased in group A which is in line with the microarrays
data. These results are consistent with the reduced con-
centrations of glycodelin in uterine flushing reported for
patients with unexplained infertility [40]. In normal
ovulatory cycles, P secretion is followed by endometrial
glycodelin synthesis in epithelial glands from 4 to 5
postovulatory days onwards [37,41]. Endometrial epi-
thelial cells stimulated in vitro with progestins showed
an increase in glycodelin transcription, synthesis, and
secretion [42] however a PR-antagonist failed to pre-
vent the induction of glycodelin [43]. In silico analysis
of PAEP gene promoter sequence identified a potential
P response element [44], however functional studies
found that the transcription factor Sp1 mediates the
effect of P and PR on human glycodelin expression in
endometrial cells [45]. We semiquantified the immu-
noreactive levels of PR-A/B, PR-B and Sp1 in endomet-
rial sections of women from groups A, B and C and
found no significant differences between the groups.
The endometrial response to the increased circulating
levels of P during the luteal phase has shown to be remark-
ably different in women with endometriosis compared to
healthy controls. Such response has been evidenced by dys-
regulated specific gene networks of P-dependent genes in
patients with endometriosis compared to non-diseasedpatients in eutopic secretory endometrium [4,39,46,47].
This transcriptional behavior has led to the concept of
‘P resistance’ which may explain the association be-
tween pelvic endometriosis and infertility. We have found
that the endometrial transcript profile from women with
repeated implantation failure (group A) presents altered
gene expression profile including several transcripts re-
ported to be P-regulated, suggesting a women from group
A have a compromised P signalling in the endometrium.
The cause of this endometrial defect is unknown, al-
though the apparent intrinsic dysregulation in P signalling
that renders the endometrium unreceptive in women with
repeated embryo implantation failure seems to be beyond
perturbations in PR expression such as chaperone proteins
involved in receptor recycling and ligand binding [48],
coregulators [49-51], as well as associated transcription
factors and a variety of upstream signal transduction
pathways capable of modifying PR and its coregulators
[52-56]. In addition, the action of the P is not limited
to the cell type in which is PR expressed since steroid
hormone regulation can be mediated also through
epithelial-stromal cross talk in the endometrium [57].
Also P can elicit a variety of rapid signalling events, in-
dependently of a direct transcriptional regulation or
even in the absence of its cognate nuclear receptors
[58] which may modulate gene expression. The mo-
lecular mechanism behind the defect in P-regulated gene
networks in the endometrium of women with repeated
embryo implantation failure is yet to be determined.Conclusions
We conclude that some cases of repeated implantation
failure could be associated with an aberrant gene expres-
sion profile, particularly of transcripts related to the im-
mune function and complement activation. Compromised
P signaling might be the underlying mechanism for such
endometrial gene expression deregulation in women with
repeated implantation failure. Future research should
focus on determining the causes of incomplete P sig-
nalling in the endometrium from these women.Abbreviations
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